drugset / Trial / NCT03673124

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124

Phase 2 Active not recruiting 51 enrolled Gynecologic Oncology Group Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

Timeline

Start
2019-05-20
Primary completion
2024-12-23
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Ribociclib Small molecule 600 mg Oral

Indications